STOCK TITAN
  1. Home
  2. Sec-filings
  3. PPBT
  4. [Form 3] PURPLE BIOTECH LTD. Initial Statement of Beneficial Ownership

Purple Biotech (PPBT) director details 3.09M shares and 2.95M options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. director Agmon Ido filed an initial ownership report showing substantial equity exposure. He beneficially owns 3,093,860 Ordinary Shares, including 2,454,167 unvested RSUs that settle in Ordinary Shares, and holds stock options over an additional 2,950,000 Ordinary Shares at low exercise prices.

Positive

  • None.

Negative

  • None.
Insider Agmon Ido
Role Director
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 300,000 shares (Direct); Ordinary Shares — 3,093,860 shares (Direct)
Footnotes (1)
  1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24, 2026. The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
Beneficially owned Ordinary Shares 3,093,860 shares Initial ownership reported by director Agmon Ido
Unvested RSUs 2,454,167 units Each RSU represents one Ordinary Share
Option 1 underlying shares 300,000 shares Stock option under 2016 Equity-Based Incentive Plan
Option 1 exercise price $0.059375 per share Expires April 24, 2028
Option 2 underlying shares 2,650,000 shares Stock option under 2016 Equity-Based Incentive Plan
Option 2 exercise price $0.00309375 per share Expires October 21, 2030
ADS ratio 1 ADS : 2,000 Ordinary Shares Representation of Ordinary Shares by ADSs
restricted stock units ("RSUs") financial
"Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Equity-Based Incentive Plan financial
"issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan"
vested and exercisable financial
"Options to purchase 274,997 Ordinary Shares are vested and exercisable"
time-based vesting conditions financial
"The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares."
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Agmon Ido
(Last)(First)(Middle)
4 OPPENHEIMER STREET
SCIENCE PARK
(Street)
REHOVOT7670104
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [ PPBT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares3,093,860(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (2) (2)Ordinary Shares300,000(2)D
Stock Option (Right to Buy) (3) (3)Ordinary Shares2,650,000(3)D
Explanation of Responses:
1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
2. Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24, 2026. The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.
3. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
/s/ Ido Agmon04/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Form 3 filing by Agmon Ido at PPBT show?

The Form 3 shows director Agmon Ido’s initial ownership in Purple Biotech. He reports 3,093,860 Ordinary Shares beneficially owned, plus stock options over 2,950,000 additional shares, giving investors a view of his total equity-based position in the company.

How many RSUs does Agmon Ido hold in Purple Biotech (PPBT)?

Agmon Ido holds 2,454,167 unvested RSUs, each representing one Ordinary Share of Purple Biotech. These RSUs vest over time based on service conditions and are settled in Ordinary Shares, aligning his compensation with the company’s long-term performance.

What stock options does Agmon Ido have in PPBT and at what prices?

He has stock options to purchase 300,000 Ordinary Shares at $0.059375 per share and 2,650,000 Ordinary Shares at $0.00309375 per share. These options were granted under Purple Biotech’s 2016 Equity-Based Incentive Plan and have multi-year expiration dates.

When do Agmon Ido’s Purple Biotech (PPBT) options vest and expire?

Options for 300,000 shares have 274,997 shares vested, with 25,003 vesting quarterly until April 24, 2026 and expiring April 24, 2028. Options for 2,650,000 shares vest quarterly until October 21, 2028 and expire on October 21, 2030.